ixekizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	5083	1143503-69-8

Description:

Molecule	Description
Synonyms: ixekizumab (genetical recombination) ixekizumab LY2439821 taltz	A humanized anti-interleukin 17 monoclonal antibody used for the treatment of PSORIASIS. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

ixekizumab (genetical recombination)
ixekizumab
LY2439821
taltz

A humanized anti-interleukin 17 monoclonal antibody used for the treatment of PSORIASIS.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
2.90	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company
Feb. 25, 2016	EMA
March 22, 2016	FDA	ELI LILLY AND CO
July 4, 2016	PMDA	Eli Lilly Japan

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Therapy interrupted	989.84	23.42	337	12944	32118	63443623
Injection site erythema	623.90	23.42	317	12964	82857	63392884
Injection site pain	565.58	23.42	346	12935	129454	63346287
Injection site swelling	548.70	23.42	244	13037	47328	63428413
Injection site reaction	503.40	23.42	245	13036	58279	63417462
COVID-19	353.20	23.42	245	13036	112858	63362883
Therapy cessation	327.81	23.42	149	13132	30308	63445433
Psoriasis	231.25	23.42	171	13110	86786	63388955
Drug ineffective	207.68	23.42	578	12703	1044187	62431554
Injection site urticaria	190.67	23.42	81	13200	13992	63461749
Injection site pruritus	184.90	23.42	116	13165	45000	63430741
Injection site warmth	175.01	23.42	78	13203	15117	63460624
Injection site rash	156.13	23.42	77	13204	18732	63457009
Illness	131.43	23.42	97	13184	48962	63426779
Ear infection	131.32	23.42	88	13193	38125	63437616
Sinusitis	102.88	23.42	176	13105	226477	63249264
Fungal infection	94.46	23.42	71	13210	36803	63438938
Injection site mass	78.96	23.42	49	13232	18607	63457134
Pharyngitis streptococcal	74.84	23.42	39	13242	10633	63465108
Nasopharyngitis	70.95	23.42	161	13120	254096	63221645
Infection	70.59	23.42	151	13130	229022	63246719
Product dose omission issue	69.44	23.42	152	13129	234161	63241580
Tooth infection	68.17	23.42	44	13237	17876	63457865
Therapy non-responder	63.79	23.42	79	13202	75822	63399919
Influenza	62.32	23.42	94	13187	108628	63367113
Injection site bruising	60.45	23.42	58	13223	41852	63433889
Inappropriate schedule of product administration	55.52	23.42	87	13194	103878	63371863
Chronic disease	52.51	23.42	11	13270	153	63475588
Psoriatic arthropathy	52.26	23.42	79	13202	91441	63384300
Urinary tract infection	52.22	23.42	147	13134	264537	63211204
Surgery	50.47	23.42	49	13232	35863	63439878
SARS-CoV-2 test positive	49.61	23.42	27	13254	8029	63467712
Device malfunction	44.86	23.42	34	13247	17823	63457918
Urticaria	43.97	23.42	103	13178	165699	63310042
Accidental underdose	43.71	23.42	13	13268	790	63474951
Acute kidney injury	43.47	23.42	3	13278	263412	63212329
Device defective	43.03	23.42	16	13265	1946	63473795
Pruritus	42.87	23.42	169	13112	361284	63114457
Upper respiratory tract infection	38.81	23.42	65	13216	81982	63393759
Intentional dose omission	38.77	23.42	23	13258	8052	63467689
Hypotension	37.61	23.42	6	13275	272598	63203143
Injection related reaction	35.09	23.42	11	13270	798	63474943
Contraindicated product administered	34.44	23.42	3	13278	217645	63258096
Wrong technique in device usage process	33.67	23.42	16	13265	3582	63472159
Inflammatory bowel disease	32.16	23.42	16	13265	3957	63471784
Injection site cellulitis	30.36	23.42	11	13270	1243	63474498
Candida infection	29.60	23.42	33	13248	28318	63447423
Confusional state	28.83	23.42	7	13274	236373	63239368
Bronchitis	28.20	23.42	73	13208	124862	63350879
Kidney infection	27.74	23.42	29	13252	23147	63452594
Meningoradiculitis	27.68	23.42	6	13275	99	63475642
Dyspnoea	27.62	23.42	61	13220	661252	62814489
Demyelinating polyneuropathy	27.24	23.42	9	13272	773	63474968
Glossodynia	26.89	23.42	3	13278	178873	63296868
Defaecation urgency	25.72	23.42	14	13267	4161	63471580
Enthesopathy	25.24	23.42	18	13263	8596	63467145
Oral candidiasis	24.60	23.42	27	13254	22771	63452970
Rash	24.26	23.42	200	13081	560671	62915070
Neutropenia	23.79	23.42	4	13277	175001	63300740

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Injection site pain	485.00	28.44	214	7501	38791	34910425
Therapy interrupted	382.03	28.44	135	7580	13562	34935654
Injection site reaction	361.72	28.44	128	7587	12905	34936311
Injection site erythema	347.77	28.44	131	7584	15768	34933448
Psoriasis	272.14	28.44	144	7571	38668	34910548
Injection site swelling	266.63	28.44	99	7616	11428	34937788
Therapy cessation	209.97	28.44	93	7622	16880	34932336
Drug ineffective	172.99	28.44	336	7379	456415	34492801
Device defective	151.90	28.44	35	7680	731	34948485
COVID-19	123.73	28.44	116	7599	77434	34871782
Nasopharyngitis	106.50	28.44	102	7613	69866	34879350
Injection site pruritus	105.13	28.44	44	7671	6939	34942277
Injection site rash	104.55	28.44	38	7677	4115	34945101
Ear infection	95.03	28.44	46	7669	10185	34939031
Ejection fraction decreased	80.37	28.44	51	7664	19103	34930113
Infection	76.30	28.44	97	7618	90818	34858398
Sinusitis	73.85	28.44	66	7649	41336	34907880
Product dose omission issue	69.51	28.44	107	7608	119604	34829612
Illness	64.29	28.44	39	7676	13490	34935726
Influenza	60.07	28.44	64	7651	49602	34899614
Injection site warmth	59.95	28.44	21	7694	2041	34947175
Injection site urticaria	59.85	28.44	21	7694	2051	34947165
Psoriatic arthropathy	59.79	28.44	43	7672	19755	34929461
Pruritus	56.11	28.44	107	7608	141874	34807342
Device malfunction	54.61	28.44	32	7683	10389	34938827
Device delivery system issue	53.90	28.44	14	7701	487	34948729
Injection site mass	53.23	28.44	27	7688	6599	34942617
Inappropriate schedule of product administration	53.04	28.44	67	7648	62229	34886987
Inflammatory bowel disease	52.83	28.44	21	7694	2899	34946317
Acute kidney injury	49.57	28.44	5	7710	304983	34644233
Drug dose omission by device	47.23	28.44	18	7697	2221	34946995
Wrong technique in device usage process	46.27	28.44	16	7699	1496	34947720
Therapy non-responder	44.78	28.44	49	7666	39097	34910119
Pharyngitis streptococcal	44.06	28.44	18	7697	2666	34946550
Injection site bruising	43.81	28.44	26	7689	8637	34940579
Fungal infection	40.04	28.44	31	7684	15904	34933312
Onycholysis	39.24	28.44	12	7703	760	34948456
Therapeutic product effect decreased	38.89	28.44	43	7672	34700	34914516
Drug interaction	38.58	28.44	3	7712	225943	34723273
Incorrect dose administered	38.38	28.44	46	7669	40469	34908747
Cutaneous lymphoma	38.34	28.44	8	7707	103	34949113
Cellulitis	37.42	28.44	52	7663	52899	34896317
Cardiac failure congestive	36.91	28.44	66	7649	83204	34866012
Intestinal haemorrhage	36.36	28.44	17	7698	3479	34945737
SARS-CoV-2 test positive	35.86	28.44	20	7695	5913	34943303
Rash	35.68	28.44	119	7596	222633	34726583
Therapeutic product effect incomplete	34.77	28.44	49	7666	50492	34898724
Carbon dioxide abnormal	34.06	28.44	8	7707	182	34949034
Arthralgia	32.87	28.44	97	7618	169944	34779272
Hypotension	32.64	28.44	5	7710	221644	34727572
Insurance issue	31.19	28.44	13	7702	2026	34947190
Tooth infection	30.83	28.44	19	7696	6752	34942464
Needle issue	29.86	28.44	18	7697	6147	34943069
Wrong schedule	29.09	28.44	7	7708	177	34949039
Injection site haemorrhage	28.98	28.44	21	7694	9747	34939469
Antibiotic therapy	28.70	28.44	6	7709	78	34949138

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Therapy interrupted	1470.50	24.24	439	14390	30902	79698657
Injection site erythema	477.54	24.24	250	14579	77947	79651612
COVID-19	467.39	24.24	316	14513	157358	79572201
Injection site pain	457.44	24.24	290	14539	129548	79600011
Injection site swelling	454.46	24.24	206	14623	46926	79682633
Therapy cessation	432.52	24.24	186	14643	37376	79692183
Injection site reaction	391.95	24.24	195	14634	54590	79674969
Psoriasis	235.36	24.24	167	14662	89420	79640139
Illness	228.74	24.24	129	14700	46382	79683177
Ear infection	223.94	24.24	115	14714	34317	79695242
Sinusitis	199.21	24.24	212	14617	195289	79534270
Nasopharyngitis	162.17	24.24	217	14612	253664	79475895
Injection site pruritus	157.37	24.24	98	14731	42185	79687374
Injection site warmth	156.17	24.24	69	14760	14738	79714821
Infection	138.35	24.24	196	14633	241516	79488043
Injection site urticaria	123.23	24.24	56	14773	12770	79716789
Injection site rash	116.77	24.24	60	14769	17894	79711665
Fungal infection	109.90	24.24	78	14751	41670	79687889
Drug ineffective	108.49	24.24	441	14388	1080472	78649087
Pharyngitis streptococcal	106.80	24.24	48	14781	10666	79718893
Product dose omission issue	103.96	24.24	174	14655	247363	79482196
Psoriatic arthropathy	96.39	24.24	94	14735	77905	79651654
Tooth infection	86.51	24.24	50	14779	18782	79710777
Surgery	83.42	24.24	60	14769	32706	79696853
Device malfunction	77.97	24.24	49	14780	21399	79708160
Influenza	76.83	24.24	107	14722	129499	79600060
SARS-CoV-2 test positive	75.73	24.24	39	14790	11677	79717882
Device defective	73.18	24.24	23	14806	1897	79727662
Acute kidney injury	68.92	24.24	8	14821	519396	79210163
Intentional dose omission	67.74	24.24	33	14796	8784	79720775
Inflammatory bowel disease	64.99	24.24	28	14801	5623	79723936
Drug interaction	61.55	24.24	4	14825	415179	79314380
Inappropriate schedule of product administration	58.77	24.24	96	14733	133532	79596027
Wrong technique in device usage process	53.13	24.24	22	14807	4006	79725553
Cellulitis	50.19	24.24	80	14749	108980	79620579
Hypotension	48.97	24.24	11	14818	440306	79289253
Chronic disease	48.15	24.24	10	14819	151	79729408
Injection site bruising	47.99	24.24	48	14781	40954	79688605
Injection site mass	46.93	24.24	35	14794	20149	79709410
Urinary tract infection	45.64	24.24	133	14696	274379	79455180
Antibiotic therapy	44.36	24.24	13	14816	846	79728713
Upper respiratory tract infection	43.50	24.24	68	14761	91100	79638459
Injection related reaction	41.95	24.24	13	14816	1023	79728536
Wrong schedule	39.89	24.24	10	14819	359	79729200
Bronchitis	39.74	24.24	80	14749	130564	79598995
Product dispensing error	37.72	24.24	26	14803	13237	79716322
Pruritus	37.57	24.24	159	14670	394489	79335070
Spinal operation	36.30	24.24	21	14808	7896	79721663
Confusional state	35.22	24.24	8	14821	317989	79411570
Localised infection	35.08	24.24	39	14790	37536	79692023
Skin disorder	34.78	24.24	37	14792	33906	79695653
Neutropenia	34.45	24.24	6	14823	287704	79441855
Manufacturing product shipping issue	34.33	24.24	7	14822	96	79729463
Cutaneous lymphoma	32.68	24.24	8	14821	260	79729299
Oropharyngeal pain	32.11	24.24	66	14763	109287	79620272
Dyspnoea	32.05	24.24	70	14759	856955	78872604
Herpes zoster	31.96	24.24	60	14769	93023	79636536
Oral candidiasis	31.61	24.24	33	14796	29595	79699964
Rash	30.67	24.24	198	14631	578160	79151399
Onycholysis	29.59	24.24	12	14817	2071	79727488
Intestinal haemorrhage	29.34	24.24	17	14812	6409	79723150
Needle issue	28.91	24.24	22	14807	13046	79716513
Carbon dioxide abnormal	28.82	24.24	8	14821	428	79729131
Thrombocytopenia	28.72	24.24	7	14822	265252	79464307
Product distribution issue	26.89	24.24	10	14819	1370	79728189
Therapeutic product effect decreased	26.81	24.24	79	14750	163784	79565775
Hospitalisation	26.63	24.24	56	14773	94180	79635379
Candida infection	26.35	24.24	34	14795	38180	79691379
Diffuse alopecia	26.35	24.24	9	14820	964	79728595
Platelet count decreased	25.77	24.24	3	14826	194661	79534898
Arthralgia	25.70	24.24	188	14641	571615	79157944
Meningoradiculitis	25.27	24.24	6	14823	171	79729388
Device delivery system issue	24.74	24.24	8	14821	723	79728836
Drug dose omission by device	24.53	24.24	15	14814	6235	79723324
Kidney infection	24.50	24.24	25	14804	21826	79707733

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC13	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
MeSH PA	D003879	Dermatologic Agents
FDA MoA	N0000191494	Interleukin-17A Antagonists
FDA EPC	N0000191495	Interleukin-17A Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Ankylosing spondylitis	indication	9631008	DOID:7147
Psoriatic arthritis	indication	156370009	DOID:9008
Plaque psoriasis	indication	200965009
Pustular psoriasis	indication	200973000
Erythrodermic psoriasis	indication	200977004
Non-radiographic axial spondyloarthritis	indication	713777005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-17A	Cytokine	Q16552	IL17_HUMAN	ANTIBODY BINDING				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
BTY153760O	UNII
D10071	KEGG_DRUG
4035606	VANDF
C3489764	UMLSCUI
CHEMBL1743034	ChEMBL_ID
DB11569	DRUGBANK_ID
9467	INN_ID
C549079	MESH_SUPPLEMENTAL_RECORD_UI
7541	IUPHAR_LIGAND_ID
1745099	RXNORM
31578	MMSL
d08425	MMSL
016752	NDDF
724037000	SNOMEDCT_US
763603002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-1445	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-1445	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-1445	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-7724	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-7724	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-7724	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections